Executive Summary
Incyte delivered net income of $1.3 billion in 2025 versus $33 million in 2024, driven by a favorable Novartis royalty settlement and 20% total revenue growth to $5.1 billion. The company launched NIKTIMVO, expanded OPZELURA internationally, and strengthened its commercial portfolio ahead of JAKAFI's 2028 patent expiration.
What happened
Incyte reported total revenues of $5.1 billion for 2025, up 21% from $4.2 billion in 2024, with product revenues reaching $4.4 billion (up 20%). JAKAFI, the company's flagship product, generated $3.1 billion in net revenues, representing 11% growth driven by increased patient demand across all three approved indications. OPZELURA expanded significantly with $679 million in revenues (up 33%), including $130 million from international markets, particularly France and Italy for vitiligo treatment. The newly launched NIKTIMVO contributed $152 million following its first quarter 2025 commercial debut. ZYNYZ revenues jumped to $66 million from $3 million following approval in squamous cell anal carcinoma during the second quarter. Total royalty revenues from partnered products (JAKAVI, OLUMIANT, TABRECTA) grew 10% to $637 million. The company resolved a multi-year royalty dispute with Novartis by paying $280 million to settle disputed amounts through December 2024, while simultaneously securing a permanent 50% reduction in the JAKAFI royalty rate for all future U.S. sales. This resulted in a $242 million gain recognized in 2025. Research and development expenses declined to $2.1 billion from $2.6 billion, primarily due to the prior year's $679 million charge related to the Escient acquisition. Operating cash flow improved substantially to $1.4 billion from $335 million. The company recorded a $76 million asset impairment on downtown Wilmington, Delaware properties classified as held for sale.
Why it matters for investors
The Novartis settlement represents a structural improvement to Incyte's margin profile, permanently reducing cost of goods on its largest product by approximately $30 million per quarter based on current sales levels. This provides greater flexibility to invest in late-stage pipeline development and new product launches as the company prepares for JAKAFI's 2028 patent expiration. The settlement also eliminated a significant balance sheet liability and reduced future cash obligations. Revenue diversification is progressing, with non-JAKAFI U.S. product revenues now representing approximately 29% of total product sales, up from 23% in 2024. OPZELURA's strong performance, particularly international expansion in vitiligo, validates the company's strategy to leverage the ruxolitinib molecule across multiple modalities and geographies. NIKTIMVO's solid launch demonstrates ability to execute co-commercialization partnerships. However, JAKAFI still accounts for 60% of total revenues and faces imminent loss of exclusivity, with multiple generic manufacturers having filed applications. The company has accrued $219 million for potential Medicaid rebate exposure related to OPZELURA being classified as a JAKAFI line extension, representing ongoing pricing and reimbursement risk. Medicare Part D program changes under the Inflation Reduction Act resulted in lower gross-to-net deductions in 2025, though the benefit may be offset by future pricing restrictions and inflation penalties. The reduced R&D spending reflects completion of the Escient acquisition accounting, but the company subsequently discontinued development of both Escient lead compounds, highlighting execution risk in business development. Cash generation improved significantly, providing resources for continued pipeline investment, potential acquisitions, and business development, though capital deployment discipline remains critical given past write-offs.
Bullish points
Novartis settlement delivered a $242 million gain while permanently cutting JAKAFI royalty expense by 50%, creating structural margin expansion worth approximately $120 million annually at current run rates.
Product revenue growth accelerated to 20% in 2025, with portfolio breadth expanding through successful launches of NIKTIMVO ($152 million first-year sales) and regulatory approval enabling ZYNYZ to reach $66 million.
OPZELURA international expansion generated $130 million in revenues with strong uptake in France and Italy, demonstrating successful geographic diversification beyond U.S. markets.
Operating cash flow surged to $1.4 billion from $335 million, reflecting improved profitability and working capital management, while cash and marketable securities grew to $3.6 billion.
Royalty revenue streams from partnered programs (JAKAVI, OLUMIANT, TABRECTA) grew 10% to $637 million, providing diversified income less affected by U.S. pricing pressures.
Bearish points
JAKAFI patent expiration in 2028 threatens 60% of total revenues ($3.1 billion), with six generic manufacturers already having filed applications and litigation ongoing with multiple parties.
The company accrued $219 million for potential Medicaid rebate liability if OPZELURA is deemed a line extension of JAKAFI, which would increase gross-to-net deductions by approximately 6.9% and materially impact profitability.
Generic competition risk intensified with settlement agreements reached with Hikma and Granules for JAKAFI, and four manufacturers filing applications for generic OPZELURA, threatening key growth drivers.
The company discontinued both lead compounds acquired from Escient after incurring $679 million in acquisition costs in 2024, demonstrating execution risk and potential for additional pipeline setbacks.
Asset impairment of $76 million on recently acquired Wilmington properties indicates potential misallocation of capital and challenges in real estate portfolio management.
Key highlights
Incyte's 2025 performance was shaped by a transformative Novartis royalty settlement that both eliminated a major liability and permanently improved gross margins on its core JAKAFI franchise. The $242 million settlement gain, combined with the 50% royalty rate reduction effective January 2025 (saving approximately $15 million in Q1 2025 alone), fundamentally altered the company's cost structure ahead of the critical 2028 patent cliff. Product portfolio expansion delivered tangible results, with OPZELURA growing 33% to $679 million (including $130 million internationally), NIKTIMVO launching successfully at $152 million, and ZYNYZ scaling to $66 million following regulatory approval in squamous cell anal carcinoma. Royalty revenues from JAKAVI, OLUMIANT, and TABRECTA grew 10% to $637 million, providing geographic and commercial diversification. Operating cash flow improved materially to $1.4 billion from $335 million as profitability expanded and working capital normalized. However, substantial risks persist, including JAKAFI's approaching loss of exclusivity with six generic filers already in litigation, the $219 million Medicaid rebate accrual threatening OPZELURA economics, ongoing pricing pressure from the Inflation Reduction Act's Medicare provisions, and execution uncertainty following the write-off of both Escient acquisition assets. The company's financial position remains solid with $3.6 billion in cash and securities and access to a $500 million undrawn credit facility, but capital deployment discipline is critical as management balances near-term commercialization investment against the imperative to build durable post-JAKAFI revenue streams.
Management commentary
Management has disclosed that JAKAFI product sales are expected to begin declining upon patent exclusivity expiration in 2028, with the company stating: 'we expect that JAKAFI product sales will begin to decline upon the expiration of our patent exclusivity in 2028.' The company acknowledged that JAKAFI revenues 'will continue to contribute a significant percentage of our total revenues over the next several years,' underscoring ongoing revenue concentration risk. Regarding the Novartis settlement, management explained that under the agreement 'we paid Novartis $280.0 million as the settlement of disputed royalties on net sales of JAKAFI in the United States through December 31, 2024, and agreed to reduce by 50% the royalty rate payable by us on future net sales of JAKAFI in the United States beginning January 1, 2025,' which resulted in a reduced royalty payment of approximately $14.9 million for the first quarter of 2025. On Medicare Part D changes, management noted: 'In 2025, we saw a reduction in our sales allowances owed under Medicare Part D, due to changes to the Part D Discount Program,' though the company also cautioned that 'the implementation of reforms could significantly reduce net sales resulting from the Medicare programs and limit our ability to increase the prices that we charge for our drugs.' Concerning the OPZELURA Medicaid line extension issue, management stated they 'have accrued approximately $218.5 million within accrued and other current liabilities on the consolidated balance sheet, relating to the incremental rebates that would be owed were OPZELURA considered a line extension of JAKAFI,' with the impact on gross-to-net deductions being approximately 6.9% in Q4 2025. Management emphasized liquidity adequacy, stating: 'We believe that our cash flow from operations, together with our cash, cash equivalents and marketable securities and funds available under our revolving credit facility, will be adequate to satisfy our capital needs for the foreseeable future.'
What to watch next
Investors should monitor:
Outcome of ongoing patent litigation with remaining generic filers for JAKAFI (Apotex, Sun Pharmaceutical, Dr. Reddy's, Eugia) and OPZELURA (Padagis, Taro, Zydus, Encube), as unfavorable rulings could accelerate generic entry before 2028.
Resolution of the lawsuit against CMS regarding OPZELURA's classification as a JAKAFI line extension for Medicaid rebate purposes, which could reverse the $219 million accrual or confirm permanent margin compression.
Progress toward revenue diversification and late-stage pipeline advancement to offset anticipated JAKAFI declines post-2028, including potential new indications or geographic expansions for existing products.
Impact of Inflation Reduction Act provisions on pricing flexibility and rebate liabilities as inflation penalty adjustments accumulate for products with price increases exceeding defined thresholds.
This summary is based solely on excerpts from the company's Form 10-K filing.
